ReviewCurrent heart failure reports2013
The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.
Review in Current heart failure reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 30 citations in OpenAlex.
- FIB-4 Index as a Non-Invasive Biomarker of Congestion and Prognosis in Heart Failure.Journal of clinical medicine · 2026Review
- How should we treat acute kidney injury caused by renal congestion?Kidney research and clinical practice · 2023Article
- The role of fibrosis, inflammation, and congestion biomarkers for outcome prediction in candidates to cardiac resynchronization therapy: is "response" the right answer?Frontiers in cardiovascular medicine · 2023Article
- Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions.BMC cardiovascular disorders · 2020Article
- The Association Between Novel Biomarkers and 1-Year Readmission or Mortality After Cardiac Surgery.The Annals of thoracic surgery · 2018Article
- Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension.Heart and vessels · 2016Article
- [Change in serum follistatin-like protein 1 and its clinical significance in children with chronic heart failure].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016Article
- Focus on renal congestion in heart failure.Clinical kidney journal · 2016Review
- Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group.Journal of cardiac failure · 2015Review
- Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a leading cause of morbidity and mortality worldwide and, despite recent advances in therapy HF hospitalization rates remains unacceptably high. Prompt identification and optimal management of HF can affect long-term outcome. A valuable tool with diagnostic, prognostic, and treatment-guiding properties in this respect will be very useful, as exemplified by natriuretic peptides. However, natriuretic peptide levels show biological variation and are dependent on age, renal function, and body mass index. Recent advances in the field of molecular biology and HF pathophysiology have led to the discovery of other novel biomarkers that may have advantages. Among others, Galectin-3 (GAL3) and sST2 are 2 promising biomarkers that have been recently developed and can be used alone or in combination with natriuretic peptides in clinical practice. In the current paper, we review the existing data regarding GAL3 and sST2 in HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.